Aurinia Pharmaceuticals (AUPH) Cash & Current Investments (2016 - 2026)

Aurinia Pharmaceuticals' Cash & Current Investments history runs 11 years deep, the most recent figure standing at $378.8 million for Q1 2026.

• Quarterly Cash & Current Investments rose 21.06% year-over-year to $378.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $378.8 million (up 21.06% YoY) and the FY2025 annual result came in at $398.0 million, up 11.02% from the prior year.
• Cash & Current Investments was $378.8 million for Q1 2026 at Aurinia Pharmaceuticals, down from $398.0 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $418.7 million in Q1 2022 and bottomed at $312.9 million in Q1 2025.
• A 5-year average of $358.3 million and a median of $351.8 million in 2025 frame the typical range for Cash & Current Investments.
• Peak annual rise in Cash & Current Investments reached 31.51% in 2022, while the deepest fall reached 16.45% in 2022.
• Aurinia Pharmaceuticals' Cash & Current Investments stood at $389.4 million in 2022, then dropped by 9.99% to $350.5 million in 2023, then advanced by 2.28% to $358.5 million in 2024, then increased by 11.02% to $398.0 million in 2025, then slipped by 4.83% to $378.8 million in 2026.
• Business Quant data shows AUPH's Cash & Current Investments at $378.8 million in Q1 2026, $398.0 million in Q4 2025, and $351.8 million in Q3 2025.